Lactoferrin may inhibit the development of cancer via its immunostimulatory and immunomodulatory activities

Pan, Sian; Weng, Huiting; Hu, Guohong; Wang, Shiwen; Zhao, Tian; Yao, Xuebiao; Liao, Libin; Zhu, Xiaopeng; Ge, Yanshan

doi:10.3892/ijo.2021.5265

Cited by 17 publications

(10 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have confirmed that LF has antitumor, antibacterial, anti‐inflammatory, and immunomodulatory effects. In the antitumor effect, LF can cause damage to different cancer cells and control the proliferation, survival, migration, and invasion of cancer cells 10,11 . In addition, LF interacts with receptors that are overexpressed on the surface of most cancer cells, such as transferrin receptor (TFR), low‐density lipoprotein (LDL), and low‐density lipoprotein receptor‐related protein (LRP), and is highly selective for cancer cells 18–20 .…”

Section: Discussionmentioning

confidence: 99%

“…In addition, as a multifunctional protein, LF has significant antitumor activity, and its potential application in cancer therapy is of great interest. Previous studies have demonstrated that LF has potent cytotoxic effects in tumors, such as breast, lung, colon, and glioma, activating significant antigrowth signals with functions such as controlling tumor proliferation, survival, migration, and invasion aspects 10,11 . In a randomized controlled phase II clinical trial, patients with advanced nonsmall cell lung cancer who received oral recombinant human LF showed significantly improved tumor progression compared to placebo, and the overall survival of patients was increased by nearly 65% 12 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Regulation of HeLa cell proliferation and apoptosis by bovine lactoferrin

Shu,

Su,

Zhao

et al. 2023

Cell Biochemistry & Function

View full text Add to dashboard Cite

Cervical cancer is one of the foremost common cancers in women. Lactoferrin (LF) has many biological functions, such as antitumor. This study aimed to explore the regulatory effect of bovine lactoferrin (bLF) on the proliferation and apoptosis of cervical cancer HeLa cells and to clarify the potential mechanism of action of bLF against HeLa cells. This study used CCK‐8, Trypan blue staining, and colony formation assays to verify the effect of bLF on HeLa cell proliferation. Hoechst 33258 fluorescence staining, AO/EB staining, and western blotting were used to determine the effects of bLF on apoptosis and autophagy in HeLa cells. We discovered that bLF significantly reduced the proliferation of HeLa cells in a dose‐ and time‐dependent manner compared to the control group. Furthermore, bLF primarily induced apoptosis in HeLa cells by increasing the expression of the proapoptotic proteins p53, Bax, and Cleaved‐caspase‐3 and downregulating the expression of the antiapoptotic protein Bcl‐2. In addition, the present study also showed that bLF treatment significantly activated autophagy‐related proteins LC3B‐II and Beclin I and down regulated the autophagosome transporter protein p62, indicating that bLF treatment can induce autophagy in HeLa cells. After pretreatment with the autophagy inhibitor, 3‐MA, which markedly found that autophagy inhibition by 3‐MA reversed bLF‐induced apoptosis, indicating that bLF can induce apoptosis by activating intracellular autophagy in HeLa cells. In the present study, our results support the theory of bLF significantly inhibited the proliferation of Hela cells by promoting apoptosis and reinforcing autophagy. The study will play an important role in therapying cervical cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Regulation of HeLa cell proliferation and apoptosis by bovine lactoferrin

Shu,

Su,

Zhao

et al. 2023

Cell Biochemistry & Function

View full text Add to dashboard Cite

show abstract

“…Elevated fecal lactoferrin levels signify an increased mucosal immune response to food or bacterial antigens and may indicate a chronic state of inflammatory gastrointestinal disease. If this is the case, a further diagnosis is recommended [ 49 , 52 , 53 , 54 ].…”

Section: Inflammatory Bowel Diseases (Ibd)mentioning

confidence: 99%

What Do NAFLD, Liver Fibrosis, and Inflammatory Bowel Disease Have in Common? Review of the Current Literature

2023

View full text Add to dashboard Cite

Liver disease is one of the most common extraintestinal manifestations of inflammatory bowel disease (IBD). Often the course of liver disease is associated with an exacerbation of the underlying disease (Crohn’s Disease/Ulcerative Colitis). Nonalcoholic steatohepatitis encompasses a wide spectrum of liver damage. The most common form is nonalcoholic fatty liver disease (NAFLD) (75–80%), and the less common but more dangerous form is nonalcoholic steatohepatitis (NASH). NAFLD is now the most common cause of chronic liver disease in developed countries and the leading indication for liver transplantation in the United States. Genetic, demographic, clinical, and environmental factors can play a role in the pathogenesis of NAFLD. The increasing prevalence of NAFLD is associated with a widespread obesity epidemic, metabolic complications, including hypertension, type 2 diabetes, and dyslipidaemia. Some of the most common manifestations of IBD are liver, biliary tract, and gallbladder diseases. The liver fibrosis process has a complex pathophysiology and is often dependent on exogenous factors such as the treatment used and endogenous factors such as the gut microbiome. However, the factors that link IBD and liver fibrosis are not yet clear. The main purpose of the review is to try to find links between IBD and selected liver diseases and to identify knowledge gaps that will inform further research.

show abstract

“…Interestingly, a crosstalk has been demonstrated between the p53 pathway and lactoferrin ( 46 ), and both proteins are components of the tears. Together, they might represent a natural barrier against the development of tumors in the anterior surface of the eye ( 56 ), as well as against infections, and in particular against SARS-CoV-2 ( 57 , 58 ).…”

Section: Mdm2 and P53 Expression In Healthy Ocular Tissuesmentioning

confidence: 99%

Therapeutic potential of the MDM2 inhibitor Nutlin-3 in counteracting SARS-CoV-2 infection of the eye through p53 activation

et al. 2022

View full text Add to dashboard Cite

Starting from the beginning of the severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) global pandemic, most of the published data has concentrated on the respiratory signs and symptoms of Covid-19 infection, underestimating the presence and importance of ocular manifestations, such as conjunctivitis, usually reported in SARS-CoV-2 infected patients. With the present review we intend to resume the ocular involvement in SARS-CoV-2 infection and the recent discoveries about the different cell types and tissues of the eye that can be directly infected by SARS-CoV-2 and propagate the infection. Moreover, reviewing literature data about p53 expression in normal and diseased eye tissues, we hypothesize that the pleiotropic protein p53 present at high levels in cornea, conjunctiva and tear film might play a protective role against SARS-CoV-2 infection. Since p53 can be easily up-regulated by using small molecule non-genotoxic inhibitors of MDM2, we propose that topical use of Nutlin-3, the prototype member of MDM2 inhibitors, might protect the anterior surface of the eye from SARS-CoV-2 infection, reducing the spreading of the virus.

show abstract

Lactoferrin may inhibit the development of cancer via its immunostimulatory and immunomodulatory activities

Cited by 17 publications

References 111 publications

Regulation of HeLa cell proliferation and apoptosis by bovine lactoferrin

Regulation of HeLa cell proliferation and apoptosis by bovine lactoferrin

What Do NAFLD, Liver Fibrosis, and Inflammatory Bowel Disease Have in Common? Review of the Current Literature

Therapeutic potential of the MDM2 inhibitor Nutlin-3 in counteracting SARS-CoV-2 infection of the eye through p53 activation

Contact Info

Product

Resources

About